Evidence map›Paper›PMID 39442521›Full record

ArticleAmerican journal of human genetics2024

Hypometric genetics: Improved power in genetic discovery by incorporating quality control flags.

Yosuke Tanigawa, Manolis Kellis

Abstract read
In one paragraph

Article in American journal of human genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yosuke TanigawaComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: tanigawa@mit.edu.
Manolis KellisComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: manoli@mit.edu.

Funding

Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIVU01DA053631 · NIDA · BROAD INSTITUTE, INC. · PI HEIMAN, MYRIAM, KELLIS, MANOLIS · 2021 to 2025
$12.6M
Mapping the vulnerable locus coeruleus pathways in aging and ADU01AG077227 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Kwanghun Chung, Li-Huei Tsai · 2022 to 2026
$9.6M
Identification of TDP-43 Modifiers Through Single-Cell Transcriptional and Epigenomic Dissection of ALS and FTLD-MNDR01NS127187 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BELZIL, VERONIQUE, DONNELLY, CHRISTOPHER JAMES · 2021 to 2025
$9.1M
Epigenomic, transcriptional and cellular dissection of Alzheimer's variantsR01AG058002 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYMAN, BRADLEY T., JAENISCH, RUDOLF · 2017 to 2021
$7.9M
Elucidating the Molecular Mechanisms of Neuropsychiatric Symptoms in Alzheimer's DiseaseR01AG062335 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS, TSAI, LI-HUEI · 2018 to 2022
$6.5M
Single-cell epigenomic and trancriptional dissection of sex-specific differences in Alzheimer’s DiseaseR01AG074003 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS, TSAI, LI-HUEI · 2021 to 2025
$5.4M
Single-cell transcriptional and epigenomic dissection of Alzheimer's Disease and Related DementiasU01NS110453 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS, TSAI, LI-HUEI · 2018 to 2020
$4.0M
Cell type specific epigenetic analysis to understand complex mechanisms underlying Alzheimer's disease phenotypesRF1AG054012 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS, TSAI, LI-HUEI · 2016 to 2016
$3.9M
Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTDR01AG067151 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELZIL, VERONIQUE, KELLIS, MANOLIS · 2021 to 2025
$3.7M
Dissection of endosomal trafficking mechanisms in Alzheimer's DiseaseRF1AG062377 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TSAI, LI-HUEI · 2018 to 2018
$3.6M
Construction of an Integrated Immune-Vascular Brain - Chip as a Platform for the Study, Drug Screening, and Treatments of Alzheimer's DiseaseUH3NS115064 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BLANCHARD, JOEL WILLIAM, KELLIS, MANOLIS · 2021 to 2023
$3.5M
Single-cell multi-region transcriptional and epigenomic dissection of VCID.RF1NS129032 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HEIMAN, MYRIAM, KELLIS, MANOLIS · 2022 to 2022
$3.1M
NHGRI NIH HHS R01 HG008155NIA NIH HHS R01 AG058002NIA NIH HHS R01 AG062335NIA NIH HHS R01 AG067151NIA NIH HHS R01 AG074003NIA NIH HHS R01 AG081017NIA NIH HHS R56 AG067151NIA NIH HHS RF1 AG054012NIA NIH HHS RF1 AG062377NIA NIH HHS U01 AG077227NIDA NIH HHS U01 DA053631NIMH NIH HHS R01 MH109978NIMH NIH HHS U01 MH119509NINDS NIH HHS R01 NS127187NINDS NIH HHS R01 NS129032NINDS NIH HHS RF1 NS129032NINDS NIH HHS U01 NS110453NINDS NIH HHS UG3 NS115064NINDS NIH HHS UH3 NS115064
6 · The paper itself

Abstract

Balancing the tradeoff between quantity and quality of phenotypic data is critical in omics studies. Measurements below the limit of quantification (BLQ) are often tagged in quality control fields, but these flags are currently underutilized in human genetics studies. Extreme phenotype sampling is advantageous for mapping rare variant effects. We hypothesize that genetic drivers, along with environmental and technical factors, contribute to the presence of BLQ flags. Here, we introduce "hypometric genetics" (hMG) analysis and uncover a genetic basis for BLQ flags, indicating an additional source of genetic signal for genetic discovery, especially from phenotypic extremes. Applying our hMG approach to n = 227,469 UK Biobank individuals with metabolomic profiles, we reveal more than 5% heritability for BLQ flags and report biologically relevant associations, for example, at APOC3, APOA5, and PDE3B loci. For common variants, polygenic scores trained only for BLQ flags predict the corresponding quantitative traits with 91% accuracy, validating the genetic basis. For rare coding variant associations, we find an asymmetric 65.4% higher enrichment of metabolite-lowering associations for BLQ flags, highlighting the impact of putative loss-of-function variants with large effects on phenotypic extremes. Joint analysis of binarized BLQ flags and the corresponding quantitative metabolite measurements improves power in Bayesian rare variant aggregation tests, resulting in an average of 181% more prioritized genes. Our approach is broadly applicable to omics profiling. Overall, our results underscore the benefit of integrating quality control flags and quantitative measurements and highlight the advantage of joint analysis of population-based samples and phenotypic extremes in human genetics studies.

Indexed as

Multifactorial InheritancePhenotypeQuality ControlGenome-Wide Association StudyHumansPolymorphism, Single NucleotideQuantitative Trait, HeritableQuantitative Trait Locigeneticsgenomicsmetabolomemetabolomicsomicspharmacokineticsproteomicsquality controltarget discoverytherapeuticstherapeutic targettranscriptomics

Identifiers

PMID39442521
PMCPMC11568753

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.